ADILNasdaqPharmaceutical PreparationsFiscal year ends December 31
ADIAL PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.62+0.13 (+3.72%)
Close on Oct 19, 2026
- Market cap
- $16.73M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
5.2%
0M of 3M shares
Institutional holders
17
4 new, 2 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
5 buys · 0 sales
Net bought $106.33K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Matthew D. Perry | 373,322 | 14.22% | 13G (passive) amendment | Jun 24, 2026 |
| Coastlands Capital LP | 262,167 | 9.98% | 13G (passive) | Jun 17, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ADIL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jane Street Group, LLC | 32,119 | 1.22% | $82.23K | New | 0.00% |
| Citadel Advisors LLC | 29,547 | 1.13% | $75.64K | New | 0.00% |
| StoneX Group Inc. | 19,699 | 0.75% | $35.67K | New | 0.00% |
| UBS Group AG | 19,147 | 0.73% | $49.02K | +18,605 | 0.00% |
| Geode Capital Management, LLC | 12,393 | 0.47% | $31.73K | −11,856 | 0.00% |
| China Universal Asset Management Co., Ltd. | 8,000 | 0.30% | $20.48K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 5,879 | 0.22% | $15.05K | – | 0.00% |
| Vanguard Capital Management LLC | 5,831 | 0.22% | $14.93K | +5,470 | 0.00% |
| Manchester Capital Management LLC | 1,923 | 0.07% | $4.92K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 1,419 | 0.05% | $3.63K | +63 | 0.00% |
| BlackRock, Inc. | 304 | 0.01% | $778 | −806 | 0.00% |
| Raffa Wealth Management, LLC | 83 | 0.00% | $212 | – | 0.00% |
| Morgan Stanley | 50 | 0.00% | $128 | – | 0.00% |
| SBI Securities Co., Ltd. | 47 | 0.00% | $120 | – | 0.00% |
| Wells Fargo & Company/Mn | 6 | 0.00% | $15 | – | 0.00% |
| Harbour Investments, Inc. | 3 | 0.00% | $8 | – | 0.00% |
| Abound Wealth Management | 1 | 0.00% | $3 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 17 | 0M | 5.2% | 4 / 3 | 2 / 2 | 0M | 0M |
| Q1 2026 | 15 | 0M | 1.4% | 14 / 0 | 1 / 0 | 0M | 0M |
| Q4 2025 | 1 | 0M | 0.1% | 0 / 1 | 0 / 0 | 0M | 0M |
| Q3 2025 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q2 2025 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q1 2025 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q4 2024 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q3 2024 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q2 2024 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q1 2024 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q4 2023 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q3 2023 | 1 | 0M | 0.0% | 0 / 0 | 1 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ADIL | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 23,596 | 0.90% | $56.63K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 361 | 0.01% | $924 | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 310 | 0.01% | $744 | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -704 | -0.03% | -$1.80K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Matt Davidson | Chief Development Officer, Director | 302,841 | 11.53% | Jun 16, 2026 |
| Tony Goodman | Chief Operating Officer, Director | 26,523 | 1.01% | Apr 9, 2026 |
| Cary J. Claiborne | Chief Executive Officer, Director | 40,417 | 1.54% | Apr 9, 2026 |
| Vinay Shah | Chief Financial Officer | 17,325 | 0.66% | Apr 9, 2026 |
| Wendy B. Young | Director | – | – | Sep 21, 2026 |
| J. Kermit Anderson | Director | – | – | Apr 9, 2026 |
| Kevin Schuyler | Director | 9,447 | 0.36% | Apr 9, 2026 |
| Robertson H. Gilliland | Director | 104,609 | 3.98% | Apr 9, 2026 |
| James W. Newman Jr. | Director | 338,463 | 12.89% | Jun 2, 2025 |
| Capital LP Coastlands | 10% owner | 388,308 | 14.79% | Jul 16, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Capital LP Coastlands 10% owner | Jul 16, 2026 | Buy | +1,233 | $2.75 | $3.39K | 388,308 |
| Capital LP Coastlands 10% owner | Jul 14, 2026 | Buy | +2,000 | $2.65 | $5.30K | 387,075 |
| Capital LP Coastlands 10% owner | Jul 10, 2026 | Buy | +1,700 | $2.70 | $4.59K | 385,075 |
| Capital LP Coastlands 10% owner | Jul 9, 2026 | Buy | +10,053 | $2.79 | $28.05K | 383,375 |
| Capital LP Coastlands 10% owner | Jun 29, 2026 | Buy | +25,000 | $2.60 | $65.00K | 373,322 |
| Matt Davidson Chief Development Officer, Director | Jun 12, 2026 | Award | +232,417 | – | – | 297,491 |
| Matt Davidson Chief Development Officer, Director | Jun 11, 2026 | Award | +61,647 | – | – | 61,647 |
| Matt Davidson Chief Development Officer, Director | Jun 11, 2026 | Award | +1,822.13 | – | – | 1,822 |
| Matt Davidson Chief Development Officer, Director | Jun 11, 2026 | Award | +101.3 | – | – | 1,923 |
| Matt Davidson Chief Development Officer, Director | Jun 11, 2026 | Award | +3,427 | – | – | 3,427 |
| Tony Goodman Chief Operating Officer, Director | Apr 7, 2026 | Award | +26,510 | – | – | 26,523 |
| Vinay Shah Chief Financial Officer | Apr 7, 2026 | Award | +17,325 | – | – | 17,325 |
| Kevin Schuyler Director | Apr 7, 2026 | Award | +9,185 | – | – | 9,213 |
| Cary J. Claiborne Chief Executive Officer, Director | Apr 7, 2026 | Award | +37,985 | – | – | 40,417 |
| Robertson H. Gilliland Director | Apr 7, 2026 | Award | +9,185 | – | – | 9,185 |
| Kevin Schuyler Director | Sep 29, 2023 | Buy | +700 | $2.74 | $1.92K | 700 |
| William B. Stilley III Director | May 23, 2023 | Award | +240,800 | – | – | 1,261,779 |
| Joseph Truluck Chief Financial Officer | May 23, 2023 | Award | +157,500 | – | – | 265,139 |
| Cary J. Claiborne Chief Executive Officer, Director | May 23, 2023 | Award | +420,000 | – | – | 1,520,000 |
| William B. Stilley III Director | Dec 30, 2022 | Returned to company | −166,667 | – | – | 1,020,979 |
| Cary J. Claiborne Chief Executive Officer, Director | Sep 20, 2022 | Award | +75,000 | $0.42 | $31.50K | 1,100,000 |
| Cary J. Claiborne Chief Executive Officer, Director | Sep 19, 2022 | Award | +25,000 | $0.43 | $10.75K | 1,025,000 |
| Cary J. Claiborne Chief Executive Officer | Aug 18, 2022 | Award | +1,000,000 | – | – | 1,000,000 |
| William B. Stilley III Chief Executive Officer, Director | Feb 23, 2022 | Award | +250,000 | – | – | 1,187,646 |
| James W. Newman Jr. Director | Dec 30, 2021 | Buy | +10,000 | $2.71 | $27.10K | 34,644 |
| James W. Newman Jr. Director | Dec 30, 2021 | Buy | +5,000 | $2.72 | $13.60K | 50,221 |
| James W. Newman Jr. Director | Dec 30, 2021 | Buy | +10,000 | $2.66 | $26.60K | 20,000 |
| Kevin Schuyler Director, 10% owner | Dec 23, 2021 | Gift | −312,990 | – | – | 0 |
| William B. Stilley III Chief Executive Officer, Director, 10% owner | Nov 30, 2021 | Buy | +10,600 | $2.75 | $29.15K | 937,646 |
| William B. Stilley III Chief Executive Officer, Director, 10% owner | Nov 29, 2021 | Buy | +10,000 | $2.59 | $25.90K | 927,046 |
| James W. Newman Jr. Director | Nov 26, 2021 | Buy | +10,000 | $2.85 | $28.50K | 34,475 |
| Bankole A. Johnson Chief Medical Officer | Oct 4, 2021 | Sale | −200,000 | – | – | 148,246 |
| Bankole A. Johnson Chief Medical Officer | Apr 6, 2021 | Sale | −150,000 | $2.50 | $375.00K | 548,336 |
| James W. Newman Jr. Director | Jan 26, 2021 | Award | +1,187 | – | – | 14,475 |
| James W. Newman Jr. Director | Jan 26, 2021 | Award | +2,544 | – | – | 152,963 |
| William B. Stilley III Chief Executive Officer, Director, 10% owner | Jan 26, 2021 | Award | +201,109 | – | – | 917,046 |
| Bankole A. Johnson Chief Medical Officer | Aug 20, 2020 | Sale | −350,000 | $1.21 | $423.50K | 1,055 |
| James W. Newman Jr. Director | Mar 27, 2020 | Buy | +5,000 | $1.42 | $7.10K | 15,000 |
| James W. Newman Jr. Director | Mar 27, 2020 | Buy | +4,644 | $1.35 | $6.27K | 14,644 |
| James W. Newman Jr. Director | Mar 27, 2020 | Buy | +10,000 | $1.34 | $13.40K | 13,288 |
| William B. Stilley III Chief Executive Officer, Director, 10% owner | Mar 26, 2020 | Buy | +12,652 | $1.47 | $18.60K | 715,937 |
| William B. Stilley III Chief Executive Officer, Director, 10% owner | Mar 25, 2020 | Buy | +12,348 | $1.13 | $13.95K | 703,285 |
| William B. Stilley III Chief Executive Officer, Director, 10% owner | Mar 3, 2020 | Award | +54,167 | – | – | 690,937 |
| Joseph Truluck Chief Financial Officer, Director | Mar 3, 2020 | Award | +27,084 | – | – | 107,639 |
| Bankole A. Johnson Chief Medical Officer, 10% owner | Dec 12, 2019 | Sale | −150,000 | $1.00 | $150.00K | 698,336 |
| Bankole A. Johnson Chief Medical Officer, 10% owner | Oct 2, 2019 | Award | +3,187 | – | – | 351,055 |
| Bankole A. Johnson Chief Medical Officer, 10% owner | Mar 29, 2019 | Buy | +30,000 | $3.47 | $104.10K | 344,768 |
| Bankole A. Johnson Chief Medical Officer, 10% owner | Mar 29, 2019 | Buy | +2,500 | $3.47 | $8.68K | 347,268 |
| Bankole A. Johnson Chief Medical Officer, 10% owner | Mar 29, 2019 | Buy | +600 | $3.30 | $1.98K | 347,868 |
| Bankole A. Johnson Chief Medical Officer, 10% owner | Mar 28, 2019 | Buy | +40,000 | $3.15 | $126.00K | 314,768 |
| Kevin Schuyler Director | Jul 31, 2018 | Buy | +90,000 | – | – | 312,990 |
| Kevin Schuyler Director | Jul 31, 2018 | Other | +89,600 | – | – | 222,990 |
| Kevin Schuyler Director | Jul 31, 2018 | Other | +144,200 | – | – | 144,200 |
| Tony Goodman Director | Jul 31, 2018 | Buy | +7,000 | – | – | 8,755 |
| Joseph Truluck Chief Financial Officer | Jul 31, 2018 | Conversion | +5,927 | – | – | 80,555 |
| Robertson H. Gilliland Director | Jul 31, 2018 | Conversion | +29,931 | – | – | 95,424 |
| Robertson H. Gilliland Director | Jul 31, 2018 | Buy | +14,000 | – | – | 109,424 |
| James W. Newman Jr. Director | Jul 31, 2018 | Buy | +10,000 | – | – | 150,419 |
| James W. Newman Jr. Director | Jul 31, 2018 | Conversion | +5,178 | – | – | 15,221 |
| James W. Newman Jr. Director | Jul 31, 2018 | Other | +20,000 | – | – | 35,094 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.